We use cookies to provide you a better experience. By continuing to use this website, you consent to the use of cookies in accordance with our Cookie Policy.

Annabel Samimy

Annabel Samimy

Managing Director

BioPharma, Biotechnology

New York

[email protected] | (212) 271-3823 | v-Card | View Coverage

Annabel Samimy joined Stifel upon its acquisition of Thomas Weisel Partners LLC in 2010. She is a Managing Director and Senior Analyst in Healthcare at Stifel, covering Biopharmaceuticals. Annabel previously covered Specialty Pharmaceuticals at Thomas Weisel. Annabel has been recognized by The Wall Street Journal’s “Best on the Street” Analysts Survey and has ranked three times in the Financial Times/StarMine Awards—twice as #2 for earnings estimates and as #3 for stock picker. She previously covered small/mid-cap Pharmaceutical and Biotechnology companies at UBS. Prior to moving to equity research, she worked in the Structured/Project Finance group at UBS. Annabel received a degree in International Relations and Economics from Tufts University and earned an MA in International Finance and International Affairs from Columbia University’s School of International and Public Affairs.